Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) issued its quarterly earnings results on Thursday. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.10), MarketWatch Earnings reports. Concert Pharmaceuticals had a negative return on equity of 69.59% and a negative net margin of 245.72%. During the same […]
Zacks Investment Research cut shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small […]
StockNews.com started coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) in a research report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock. A number of other research analysts have also recently commented on the company. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a […]